[PDF][PDF] Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AEl

E Horak, F Hartmann, K Garmestani, C Wu… - Journal of Nuclear …, 1997 - Soc Nuclear Med
HER2/neu monoclonal antibody AE1 conjugated to 212Pb, 212Bi being the daughter and
thus the source of the alpha-particle and beta emissions. A bifunctional derivative of …

TAG-72–targeted α-radionuclide therapy of ovarian cancer using 225Ac-labeled DOTAylated-huCC49 antibody

M Minnix, L Li, PJ Yazaki, AD Miller… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Radioimmunotherapy, an approach using radiolabeled antibodies, has had minimal
success in the clinic with several β-emitting radionuclides for the treatment of ovarian …

Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution

MR Zalutsky, FJ Xu, Y Yu, CF Foulon, XG Zhao… - Nuclear medicine and …, 1999 - Elsevier
Monoclonal antibody (MAb) internalization can have a major effect on tumor retention of
radiolabel. Two anti-HER-2/neu MAbs (TA1 and 520C9) were radioiodinated using the …

A comparative evaluation of the chelators H4octapa and CHX-A ″-DTPA with the therapeutic radiometal 90Y

EW Price, KJ Edwards, KE Carnazza, SD Carlin… - Nuclear medicine and …, 2016 - Elsevier
Objectives To compare the radiolabeling performance, stability, and practical efficacy of the
chelators CHX-A ″-DTPA and H 4 octapa with the therapeutic radiometal 90 Y. Methods …

Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice

AC Steffen, A Orlova, M Wikman, FY Nilsson… - European journal of …, 2006 - Springer
Purpose Targeted delivery of radionuclides for diagnostic and therapeutic applications has
until recently largely been limited to receptor ligands, antibodies and antibody-derived …

Radioiodinated antibody targeting of the HER-2/neu oncoprotein

FJ Xu, YH Yu, DS Bae, XG Zhao, SK Slade… - Nuclear medicine and …, 1997 - Elsevier
The HER-2/neu oncogene encodes a 185 kDa phosphoglycoprotein that is overexpressed
in breast, ovarian and other cancers. Seven monoclonal antibodies reactive with this …

α-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: outcome related to measured tumor size and mean absorbed dose

J Elgqvist, H Andersson, T Bäck… - Journal of Nuclear …, 2006 - Soc Nuclear Med
The purpose of this work was to (a) investigate the efficacy of radioimmunotherapy using
211At-MX35 F (ab′) 2 or 211At-Rituximab F (ab′) 2 (nonspecific antibody) against …

Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with 211At-labeled monoclonal …

J Elgqvist, H Andersson, T Bäck… - Journal of Nuclear …, 2005 - Soc Nuclear Med
The purpose of this study was to investigate the therapeutic efficacy of—and to estimate the
absorbed dose to—tumor cells from radioimmunotherapy (RIT) in an ovarian cancer model …

Radiolabeled Antibody Targeting of the HER-2/neu Oncoprotein

K De Santes, D Slamon, SK Anderson, M Shepard… - Cancer research, 1992 - AACR
The HER-2/neu oncogene encodes a M r 185,000 transmembrane phosphoglycoprotein
which is overexpressed in 25–35% of breast and ovarian neoplasms and portends a poor …

Methodology for labeling proteins and peptides with lead-212 (212Pb)

KE Baidoo, DE Milenic, MW Brechbiel - Nuclear medicine and biology, 2013 - Elsevier
INTRODUCTION: Alpha particles possess an exquisite degree of cytotoxicity when
employed for targeted α-particle therapy (TAT) or radioimmunotherapy (RIT). 212Pb, which …